Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsHyung Chun, MD, FAHA
Associate Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct
Appointments
Cardiovascular Medicine
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Cardiovascular Medicine
- Internal Medicine
- Pathology Research
- Pulmonary Vascular Disease Program
- Yale Ventures
Education & Training
- Chief Fellow
- Stanford University (2009)
- Fellowship
- Stanford University (2009)
- Residency
- Stanford University (2004)
- MD
- Johns Hopkins University School of Medicine (2002)
- Cloisters Scholar
- HHMI (2001)
- BA
- Harvard University, Biochemical Sciences (1995)
Research
Copy Link
Overview
Medical Research Interests
Biological Science Disciplines; Cardiovascular Diseases; Endocrine System Diseases; Respiratory Tract Diseases
ORCID
0000-0003-3508-2678
Research at a Glance
Yale Co-Authors
Frequent collaborators of Hyung Chun's published research.
Publications Timeline
A big-picture view of Hyung Chun's research output by year.
Research Interests
Research topics Hyung Chun is interested in exploring.
Hanming Zhang, PhD
Alexander B. Pine, MD, PhD
Christine Won, MD, MSc, BA
Adam V Wisnewski, PhD, D(ABMLI)
Akiko Iwasaki, PhD
Albert Icksang Ko, MD
44Publications
6,879Citations
Cardiovascular Diseases
Publications
2023
Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome
Singh I, Leitner B, Wang Y, Zhang H, Joseph P, Lutchmansingh D, Gulati M, Possick J, Damsky W, Hwa J, Heerdt P, Chun H. Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome. Pulmonary Circulation 2023, 13: e12220. PMID: 37091121, PMCID: PMC10113513, DOI: 10.1002/pul2.12220.Peer-Reviewed Original ResearchCitationsAltmetricConceptsInvasive cardiopulmonary exercise testPASC patientsPost-acute sequelaeAcute sequelaeInfection syndromeUnexplained exertional intoleranceCardiopulmonary exercise testSystemic oxygen deliveryPersistent inflammatory stateVenous blood plasmaExertional intolerancePeak exerciseEndothelial dysfunctionHemodynamic profileInflammatory stateExercise testFibrotic processPathophysiological hallmarkAberrant protein expressionExpression of proteinsOxygen deliveryOxygen extractionProteomic profilingPatientsPhysiologic responses
2022
LncRNA Airn alleviates diabetic cardiac fibrosis by inhibiting activation of cardiac fibroblasts via a m6A-IMP2-p53 axis
Peng T, Liu M, Hu L, Guo D, Wang D, Qi B, Ren G, Hu C, Zhang F, Chun H, Song L, Hu J, Li Y. LncRNA Airn alleviates diabetic cardiac fibrosis by inhibiting activation of cardiac fibroblasts via a m6A-IMP2-p53 axis. Biology Direct 2022, 17: 32. PMID: 36384975, PMCID: PMC9670606, DOI: 10.1186/s13062-022-00346-6.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdeno-associated virusCardiac fibrosisDiabetic cardiomyopathyInsulin-like growth factor 2 mRNA-binding protein 2Cardiac fibroblastsDiabetic heartAblation of p53Development of diabetic cardiomyopathyDevelopment of cardiac fibrosisPathogenesis of cardiac fibrosisActivation of cardiac fibroblastsIn vitroMechanisms of cardiac fibrosisAnti-fibrotic effectsDiabetic cardiac fibrosisInhibitory effectGrowth factor 2 mRNA-binding protein 2Cell cycle arrestMethodsDiabetes mellitusCardiac dysfunctionFibroblast-myofibroblast transitionStreptozotocin injectionCardiac functionBackgroundCardiac fibrosisFibrosisEndothelial β‐arrestins regulate mechanotransduction by the type II bone morphogenetic protein receptor in primary cilia
Park S, Ma Z, Zarkada G, Papangeli I, Paluri S, Nazo N, Rivera‐Molina F, Toomre D, Rajagopal S, Chun H. Endothelial β‐arrestins regulate mechanotransduction by the type II bone morphogenetic protein receptor in primary cilia. Pulmonary Circulation 2022, 12: e12167. PMID: 36532314, PMCID: PMC9751664, DOI: 10.1002/pul2.12167.Peer-Reviewed Original ResearchCitationsAltmetricConceptsType II bone morphogenetic protein receptorBone morphogenetic protein receptorMorphogenetic protein receptorΒ-arrestinΒ-arrestin 1Primary ciliaEndothelial-specific deletionBMPR-IIProtein receptorsTransport protein complexTranscription factor phosphorylationSpecific deletionArrestin knockdownEndothelial cellsCell surface receptorsPrimary endothelial cellsEndothelial cell behaviorEpigenetic elementsProtein complexesTranscription factorsKey transducerFactor phosphorylationTransmembrane receptorsIntracellular proteinsStress responseBMPR1A promotes ID2–ZEB1 interaction to suppress excessive endothelial to mesenchymal transition
Lee H, Adachi T, Pak B, Park S, Hu X, Choi W, Kowalski PS, Chang CH, Clapham KR, Lee A, Papangeli I, Kim J, Han O, Park J, Anderson DG, Simons M, Jin S, Chun HJ. BMPR1A promotes ID2–ZEB1 interaction to suppress excessive endothelial to mesenchymal transition. Cardiovascular Research 2022, 119: 813-825. PMID: 36166408, PMCID: PMC10409893, DOI: 10.1093/cvr/cvac159.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsBone Morphogenetic Protein Receptors, Type IEndothelial CellsEndotheliumEpithelial-Mesenchymal TransitionHypertension, PulmonaryInhibitor of Differentiation Protein 2LungMicePulmonary Arterial HypertensionReceptor, Transforming Growth Factor-beta Type IIZinc Finger E-box-Binding Homeobox 1ConceptsPathogenesis of PAHPulmonary arterial hypertensionEndothelial cellsOnset of PAHAmeliorate pulmonary arterial hypertensionPotential novel therapeutic targetType 1 receptorType 2 receptorEndothelial-mesenchymal transitionNovel therapeutic targetGrowth factor-beta stimulationSmooth muscle cellsBone morphogenetic proteinPAH patientsArterial hypertensionVascular disordersBMP type 1 receptorsResponse of ECsAdult miceEndoMTTherapeutic targetBeta stimulationPathogenesisMesenchymal transitionMuscle cells
2021
Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, Won CH, Chun HJ. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. The Lancet Microbe 2021, 3: e4-e5. PMID: 34901896, PMCID: PMC8641954, DOI: 10.1016/s2666-5247(21)00306-2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsHospitalisation among vaccine breakthrough COVID-19 infections
Juthani PV, Gupta A, Borges KA, Price CC, Lee AI, Won CH, Chun HJ. Hospitalisation among vaccine breakthrough COVID-19 infections. The Lancet Infectious Diseases 2021, 21: 1485-1486. PMID: 34506735, PMCID: PMC8423430, DOI: 10.1016/s1473-3099(21)00558-2.Peer-Reviewed Original ResearchCitationsAltmetricAuthor Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Author Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1309-1309. PMID: 34145437, PMCID: PMC8212078, DOI: 10.1038/s41591-021-01416-4.Commentaries, Editorials and LettersCitationsAltmetricIncreased complement activation is a distinctive feature of severe SARS-CoV-2 infection
Ma L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSevere SARS-CoV-2 infectionSARS-CoV-2 infectionIntensive care unitComplement activationRespiratory failureEndothelial injuryCOVID-19Non-COVID cohortPersonalized clinical trialsAcute respiratory failureInvasive mechanical ventilationSevere COVID-19Tertiary care centerAlternative complement pathwayICU admissionCritical illnessCare unitMechanical ventilationRisk prognosticationWashington University SchoolWorse outcomesCare centerClinical trialsHigh riskPatientsDelayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1178-1186. PMID: 33953384, PMCID: PMC8785364, DOI: 10.1038/s41591-021-01355-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDeceased patientsAntibody levelsAntibody responseDisease severityAnti-S IgG levelsCOVID-19 disease outcomesFatal COVID-19Impaired viral controlWorse clinical progressionWorse disease severitySevere COVID-19Length of hospitalizationImmunoglobulin G levelsHumoral immune responseCoronavirus disease 2019COVID-19 mortalityCOVID-19Domain (RBD) IgGSeroconversion kineticsDisease courseIgG levelsClinical parametersClinical progressionHumoral responseDisease onsetA neutrophil activation signature predicts critical illness and mortality in COVID-19
Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCritical illnessHealth system databaseNeutrophil activationCOVID-19Neutrophil activation signatureSevere COVID-19Intensive care unitGranulocyte colony-stimulating factorHigh mortality rateColony-stimulating factorSystem databaseHepatocyte growth factorClinical decompensationNeutrophil countImmune hyperactivationCare unitEarly elevationLipocalin-2Interleukin-8Longitudinal cohortClinical dataMortality ratePatientsIllnessActivation signature
Academic Achievements & Community Involvement
Copy Link
Activities
activity American Society for Clinical Investigation
04/01/2016 - PresentProfessional OrganizationsMemberactivity Fellow of the American Heart Association
11/13/2015 - PresentProfessional OrganizationsMember
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email